Clinical Trials Using Lenalidomide

Clinical Trials Using Lenalidomide - NCI

This phase III trial compares the effect of usual treatment (lenalidomide) to using daratumumab/rHuPH20 plus the usual treatment after stem cell ...

NCT00689936 - ClinicalTrials.gov

Randomized Trial of Lenalidomide Versus Observation in ...

Progression-free survival was significantly longer with lenalidomide compared with observation (hazard ratio, 0.28; 95% CI, 0.12 to 0.62; P = .

Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy ...

Lenalidomide Approved as First-Line Therapy in Multiple Myeloma · Mechanism of Action · Dosing and Administration · Clinical Trial: FIRST · Adverse Events.

Lenalidomide Myeloma Trials - SparkCures

Lenalidomide is an oral immunomodulatory drug that may help the immune system kill cancer cells. It may also prevent the growth of new blood vessels that ...

A Phase II Clinical Trial of Lenalidomide Intensification in Patients ...

(1,2) Multiple randomized trials have now demonstrated that post HCT maintenance therapy with lenalidomide at doses ranging from 5 to 15 mg daily or 21 of 28 ...

Search for lenalidomide - Clinical Trials register

Clinical Trials Information System (CTIS). The EU Clinical Trials Register currently displays 44211 clinical trials with a EudraCT protocol, of which 7331 ...

Treatment Clinical Trials for Multiple Myeloma/Plasma Cell Myeloma

This phase III trial compares the effect of usual treatment (lenalidomide) to using daratumumab/rHuPH20 plus the usual treatment after stem cell ...

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients ...

In a randomized trial that included both younger and older patients with newly diagnosed multiple myeloma, lenalidomide plus low-dose ...

Clinical Trial Finder Tool - Multiple Myeloma Research Foundation

The trial will test the efficacy of using selinexor with daratumumab, lenalidomide, and dexamethasone (DRd) as a first-line treatment for multiple myeloma (MM).

Lenalidomide maintenance versus observation for patients with ...

The results of the Myeloma XI trial contribute to a body of evidence that suggests that the use of lenalidomide as maintenance therapy should be ...

Phase 1/2 study of lenalidomide combined with low-dose ...

We have previously shown in a retrospective analysis that lenalidomide combined with continuous low-dose cyclophosphamide and prednisone (REP) had remarkable ...

Clinical Efficacy of Lenalidomide in Patients With Relapsed or ...

The antitumor activity of lenalidomide noted in this study is exciting; however, the hematologic toxicity observed remains a concern at the 25-mg starting dose.

Lenalidomide plus Dexamethasone for High-Risk Smoldering ...

Lenalidomide-based treatment was associated with a significant delay in progression to symptomatic myeloma; 3 years after study entry, 77% of ...

REVLIMID® (lenalidomide) - Official Patient Website

REVLIMID should not be used to treat people who have chronic lymphocytic leukemia (CLL) unless they are participants in a controlled clinical trial. It is not ...

A randomized phase 2 study of lenalidomide therapy for patients ...

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

UCSF Multiple Myeloma Clinical Trials — San Francisco Bay Area

Sorry, in progress, not accepting new patients. In this research study, we are looking to explore the drug combination, lenalidomide ...

Search for a clinical trial - Orphanet

A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with ...

A trial looking at lenalidomide, bortezomib and vorinostat for ...

79% of those who'd had lenalidomide; 76% of those who hadn't had lenalidomide. When they looked at how many people in the non intensive arm were ...

Lenalidomide: an update on evidence from clinical trials

The benefits of lenalidomide-based treatment regimens can be optimized by initiating treatment early in the disease course, either as a frontline treatment or ...